Howard Gendelman

List of Articles by Year
in descending order

Source: //exaly.com/author-pdf/6142967/publications.pdf

Version: 2025-02-01

413 peer-reviewed articles	26,032 peer-reviewed citations	5670 80 peer-reviewed h-index	52546 6.81 score
510 documents	34236 doc citations	4212 92 h-index	52715 citing authors

#	Article	IF	Citations
1	CCR5-ligand decorated rilpivirine lipid-based nanoparticles for sustained antiretroviral responses. Nature Communications, 2025, 16, .	10.8	8
2	The 29th Scientific Conference of the Society on NeuroImmune Pharmacology in Omaha, NE, June 8–12, 2025. NeuroImmune Pharmacology and Therapeutics, 2025, 4, 131-192.	0.7	1
3	Adaptive immunity in the pathogenesis and treatments of Parkinson's disease. NeuroImmune Pharmacology and Therapeutics, 2025, 4, 273-284.	0.7	7
4	Unique molecular signatures in rebound viruses from antiretroviral drug and CRISPR-treated HIV-1-infected humanized mice. Communications Biology, 2025, 8, .	3.1	4
5	A scalable ultra-long-acting tenofovir phosphonate prodrug sustains HBV suppression. Science Advances, 2025, 11, .	8.1	5
6	Polymer Delivery Systems for Long-Acting Antiretroviral Drugs. Pharmaceutics, 2024, 16, 183.	4.2	13
7	Accelerated Neuroimmune Dysfunction in Aged HIV-1-Infected Humanized Mice. Pharmaceuticals, 2024, 17, 149.	3.3	6
8	Neuroprotective mushrooms. NeuroImmune Pharmacology and Therapeutics, 2024, 3, 129-137.	0.7	6
9	Development of an extended action fostemsavir lipid nanoparticle. Communications Biology, 2024, 7, .	3.1	9
10	The potential for treg-enhancing therapies in nervous system pathologies. Clinical and Experimental Immunology, 2023, 211, 108-121.	2.3	56
11	CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	5.2	77
12	An open-label multiyear study of sargramostim-treated Parkinson's disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers. Translational Neurodegeneration, 2023, 12, .	8.1	33
13	Humanized Mice for Studies of HIV-1 Persistence and Elimination. Pathogens, 2023, 12, 879.	2.1	29
14	Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection. Advanced Drug Delivery Reviews, 2023, 200, 115009.	12.5	48
15	Immune senescence in aged APP/PS1 mice. NeuroImmune Pharmacology and Therapeutics, 2023, 2, 317-330.	0.7	10
16	Clinical biomarkers for Lewy body diseases. Cell and Bioscience, 2023, 13, .	3.5	16
17	Amyloid-β specific regulatory T cells attenuate Alzheimer's disease pathobiology in APP/PS1 mice. Molecular Neurodegeneration, 2023, 18, .	9.9	69
18	Oral antivirals for the prevention and treatment of SARS-CoV-2 infection. AIDS Reviews, 2022, 24, .	0.3	25

#	Article	IF	Citations
19	Prodrug Therapies for Infectious and Neurodegenerative Diseases. Pharmaceutics, 2022, 14, 518.	4.2	9
20	Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis. ACS Chemical Neuroscience, 2022, 13, 1232-1244.	2.7	34
21	The 2022 outbreak and the pathobiology of the monkeypox virus. Journal of Autoimmunity, 2022, 131, 102855.	3.8	461
22	Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation. Nature Communications, 2022, 13, .	10.8	44
23	Interleukin-2 expands neuroprotective regulatory T cells in Parkinson's disease. NeuroImmune Pharmacology and Therapeutics, 2022, 1, 43-50.	0.7	20
24	Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease. Clinical and Translational Medicine, 2022, 12, .	4.1	25
25	Development of an extended half-life GM-CSF fusion protein for Parkinson's disease. Journal of Controlled Release, 2022, 348, 951-965.	8.1	35
26	Therapeutic Strategies for Immune Transformation in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, S201-S222.	2.2	34
27	Introducing NeuroImmune Pharmacology and Therapeutics (NIPT), the official journal of the Society on NeuroImmune Pharmacology (SNIP). NeuroImmune Pharmacology and Therapeutics, 2022, 1, 1-2.	0.7	0
28	Animal models for studies of HIV-1 brain reservoirs. Journal of Leukocyte Biology, 2022, 112, 1285-1295.	1.7	28
29	Dual-Peak Lorentzian CEST MRI for antiretroviral drug brain distribution. NeuroImmune Pharmacology and Therapeutics, 2022, .	0.7	1
30	An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression. Science Advances, 2022, 8, .	8.1	16
31	HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment. Pharmaceuticals, 2022, 15, 1533.	3.3	19
32	Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain, 2021, 144, 288-309.	5.9	271
33	Europium sulfide nanoprobes predict antiretroviral drug delivery into HIV-1 cell and tissue reservoirs. Nanotheranostics, 2021, 5, 417-430.	4.5	6
34	Diagnostics for SARS-CoV-2 infections. Nature Materials, 2021, 20, 593-605.	23.7	784
35	A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention. Journal of NeuroImmune Pharmacology, 2021, 16, 270-288.	3.6	45
36	Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca2+ homeostasis in skeletal muscles. Antiviral Research, 2021, 187, 104975.	2.7	5

#	Article	IF	Citations
37	Nanocarrier vaccines for SARS-CoV-2. Advanced Drug Delivery Reviews, 2021, 171, 215-239.	12.5	94
38	Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson's disease. Biomaterials, 2021, 272, 120786.	9.5	52
39	Chemical exchange saturation transfer for detection of antiretroviral drugs in brain tissue. Aids, 2021, 35, 1733-1741.	1.5	8
40	Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease. EBioMedicine, 2021, 67, 103380.	6.6	52
41	The Immunopathobiology of SARS-CoV-2 Infection. FEMS Microbiology Reviews, 2021, 45, .	9.6	14
42	Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir. Nature Communications, 2021, 12, .	10.8	43
43	Humanized Mice for Infectious and Neurodegenerative disorders. Retrovirology, 2021, 18, .	2.7	38
44	Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment. Molecular Neurobiology, 2021, 58, 5703-5721.	3.0	25
45	Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles. Nature Communications, 2021, 12, .	10.8	50
46	Pharmacotherapeutics of SARS-CoV-2 Infections. Journal of NeuroImmune Pharmacology, 2021, 16, 12-37.	3.6	6
47	Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions. Frontiers in Immunology, 2021, 12, .	3.3	45
48	CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination. EBioMedicine, 2021, 73, 103678.	6.6	55
49	CD4+ effector T cells accelerate Alzheimer's disease in mice. Journal of Neuroinflammation, 2021, 18, .	6.1	133
50	A Link Between Methylglyoxal and Heart Failure During HIV-1 Infection. Frontiers in Cardiovascular Medicine, 2021, 8, .	1.6	8
51	Synthesis and Characterization of Long-Acting Darunavir Prodrugs. Molecular Pharmaceutics, 2020, 17, 155-166.	3.2	17
52	Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. Theranostics, 2020, 10, 630-656.	8.1	40
53	Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking. Biomaterials, 2020, 231, 119669.	9.5	25
54	The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. Journal of NeuroImmune Pharmacology, 2020, 15, 359-386.	3.6	476

#	Article	IF	Citations
55	Elucidating the pathogenic mechanisms of AD brain-derived, tau-containing extracellular vesicles: Highly transmissible and preferential propagation to GABAergic neurons. Alzheimer's and Dementia, 2020, 16, .	0.8	1
56	HIV-1-Associated Left Ventricular Cardiac Dysfunction in Humanized Mice. Scientific Reports, 2020, 10, .	2.7	10
57	Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Molecular Neurodegeneration, 2020, 15, .	9.9	129
58	Amplification of Replication Competent HIV-1 by Adoptive Transfer of Human Cells From Infected Humanized Mice. Frontiers in Cellular and Infection Microbiology, 2020, 10, .	2.8	12
59	Neuroprotective Activities of Long-Acting Granulocyte–Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice. Neurotherapeutics, 2020, 17, 1861-1877.	3.9	32
60	Pathways towards human immunodeficiency virus elimination. EBioMedicine, 2020, 53, 102667.	6.6	22
61	Immunotherapy for Parkinson's disease. Neurobiology of Disease, 2020, 137, 104760.	3.5	95
62	A year-long extended release nanoformulated cabotegravir prodrug. Nature Materials, 2020, 19, 910-920.	23.7	108
63	A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102185.	2.3	19
64	Synthesis of a long acting nanoformulated emtricitabine ProTide. Biomaterials, 2019, 222, 119441.	9.5	21
65	Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. Nature Communications, 2019, 10, .	10.8	286
66	A long acting nanoformulated lamivudine ProTide. Biomaterials, 2019, 223, 119476.	9.5	35
67	Creation of a long-acting rilpivirine prodrug nanoformulation. Journal of Controlled Release, 2019, 311-312, 201-211.	8.1	29
68	A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson's Disease. Frontiers in Cellular Neuroscience, 2019, 13, .	2.4	43
69	Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases. Drug Discovery Today, 2019, 24, 873-882.	5.0	67
70	Human Interleukin-34 facilitates microglia-like cell differentiation and persistent HIV-1 infection in humanized mice. Molecular Neurodegeneration, 2019, 14, .	9.9	76
71	In Appreciation for a Job Well Done!. Journal of NeuroImmune Pharmacology, 2019, 14, 1-1.	3.6	1
72	Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice. Frontiers in Immunology, 2019, 10, .	3.3	30

#	Article	IF	Citations
73	The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture. Trends in Microbiology, 2019, 27, 593-606.	7.0	36
74	Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages. Journal of NeuroImmune Pharmacology, 2019, 14, 44-51.	3.6	6
75	Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques. Aids, 2019, 33, 585-588.	1.5	8
76	Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 564-571.	5.0	26
77	Neurotheranostics as personalized medicines. Advanced Drug Delivery Reviews, 2019, 148, 252-289.	12.5	114
78	Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 272-280.	2.3	12
79	Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Journal of NeuroVirology, 2018, 24, 398-410.	1.1	20
80	Design of mannosylated oral amphotericin B nanoformulation: efficacy and safety in visceral leishmaniasis. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 521-531.	3.6	33
81	Creation of a long-acting nanoformulated dolutegravir. Nature Communications, 2018, 9, .	10.8	126
82	Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2018, 153, 248-259.	2.2	15
83	Optimizing the Preparation and Stability of Decorated Antiretroviral Drug Nanocrystals. Nanomedicine, 2018, 13, 871-885.	2.5	28
84	Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer's disease mice. Journal of Neuroimmunology, 2018, 319, 80-92.	1.7	77
85	Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials, 2018, 151, 53-65.	9.5	90
86	O2-01-02: CHARACTERIZATION OF HUMAN ALZHEIMER'S DISEASE BRAIN-DERIVED EXOSOMES. Alzheimer's and Dementia, 2018, 14, .	0.8	1
87	Biodegradable polyanhydride-based nanomedicines for blood to brain drug delivery. Journal of Biomedical Materials Research - Part A, 2018, 106, 2881-2890.	2.8	26
88	Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. Biomaterials, 2018, 185, 174-193.	9.5	32
89	EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment. PLoS Pathogens, 2018, 14, e1007061.	2.9	93
90	Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics, 2018, 8, 256-276.	8.1	51

#	Article	IF	Citations
91	ProTide generated long-acting abacavir nanoformulations. Chemical Communications, 2018, 54, 8371-8374.	2.4	19
92	URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer's disease. Journal of Neuroinflammation, 2018, 15, .	6.1	43
93	Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease. Molecular Neurodegeneration, 2018, 13, .	9.9	61
94	Modulating Cellular Autophagy for Controlled Antiretroviral Drug Release. Nanomedicine, 2018, 13, 2139-2154.	2.5	9
95	Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress. Molecular Neurobiology, 2018, 56, 2896-2907.	3.0	27
96	HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication. Journal of NeuroImmune Pharmacology, 2018, 14, 52-67.	3.6	43
97	Long-acting slow effective release antiretroviral therapy. Expert Opinion on Drug Delivery, 2017, 14, 1281-1291.	3.7	65
98	The cortical signature of symptom laterality in Parkinson's disease. NeuroImage: Clinical, 2017, 14, 433-440.	2.2	74
99	P-D7 Synthesis and Characterization of a Long Acting Nanoformulated Dolutegravir. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 92.	1.2	0
100	Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e75-e83.	1.2	45
101	P-D5 Synthesis and characterization of core-–shell silica cobalt ferrite nanoparticles as a first step towards developing ultrasensitive MRI probes for long-acting antiretroviral drug biodistribution testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 91.	1.2	1
102	A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology, 2017, 14, .	2.7	109
103	Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging. Acta Biomaterialia, 2017, 49, 507-520.	6.7	33
104	I-106 Special lecture. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 68.	1.2	0
105	P-D2 Macrophage Autophagy Facilitates Sustained Release of Nanoformulated Antiretroviral Drugs From Autophagosomal Depots Enhances Anti-HIV-1 Activities. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 89.	1.2	0
106	P-D4 Evaluation of Combination Long-Acting Nanoformulated Antiretroviral Therapy in HIV-1 Infected huPBL NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ MICE. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 90.	1.2	0
107	P-D9 Development of a Next Generation Long-Acting Nanoformulated Cabotegravir. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 93.	1.2	0
108	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. Npj Parkinson's Disease, 2017, 3, .	4.4	137

#	Article	IF	Citations
109	P-D8 Macrophage exosomes as novel antiretroviral drug delivery platforms. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 92.	1.2	0
110	Proteomic analysis of mesenchymal to Schwann cell transdifferentiation. Journal of Proteomics, 2017, 165, 93-101.	1.9	25
111	Development of mannose-anchored Thiolated Amphotericin B Nanocarriers for Treatment of Visceral Leishmaniasis. Nanomedicine, 2017, 12, 99-115.	2.5	90
112	Thank You!. Journal of NeuroImmune Pharmacology, 2017, 12, 565-565.	3.6	0
113	Systemic HIV-1 infection produces a unique glial footprint in humanized mouse brains. DMM Disease Models and Mechanisms, 2017, , .	1.2	16
114	Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. Journal of Clinical Investigation, 2017, 127, 857-873.	6.6	49
115	Quiet connections: Reduced fronto-temporal connectivity in nondemented Parkinson's Disease during working memory encoding. Human Brain Mapping, 2016, 37, 3224-3235.	2.3	59
116	Neuropharmacologic Approaches to Restore the Brain's Microenvironment. Journal of NeuroImmune Pharmacology, 2016, 11, 484-494.	3.6	10
117	HIV-1 cellular and tissue replication patterns in infected humanized mice. Scientific Reports, 2016, 6, .	2.7	65
118	The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation. Journal of Neuroinflammation, 2016, 13, .	6.1	29
119	Development and Characterization of a long-acting Nanoformulated Abacavir Prodrug. Nanomedicine, 2016, 11, 1913-1927.	2.5	49
120	Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease. Neurotherapeutics, 2016, 13, 635-646.	3.9	28
121	The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 109-122.	2.3	29
122	Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. Current Opinion in Pharmacology, 2016, 26, 87-95.	2.8	58
123	Cathepsin B Improves ß-Amyloidosis and Learning and Memory in Models of Alzheimer's Disease. Journal of NeuroImmune Pharmacology, 2016, 12, 340-352.	3.6	70
124	Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy. PLoS ONE, 2015, 10, e0145966.	1.5	13
125	Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice. Journal of Neuroscience, 2015, 35, 16463-16478.	2.3	88
126	Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 715-729.	2.3	51

#	Article	IF	Citations
127	Comprehensive bioimaging with fluorinated nanoparticles using breathable liquids. Nature Communications, 2015, 6, .	10.8	54
128	Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials, 2015, 41, 141-150.	9.5	60
129	Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages. Retrovirology, 2015, 12, .	2.7	34
130	Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice. Antiviral Research, 2015, 120, 85-88.	2.7	26
131	Potential of N-acetylated-para-aminosalicylic acid to accelerate manganese enhancement decline for long-term MEMRI in rodent brain. Journal of Neuroscience Methods, 2015, 251, 92-98.	1.7	2
132	Granulocyte-Macrophage Colony Stimulating Factor Exerts Protective and Immunomodulatory Effects in Cortical Trauma. Journal of Neuroimmunology, 2015, 278, 162-173.	1.7	35
133	Presenilin-1 familial Alzheimer's disease mutation alters hippocampal neurogenesis and memory function in CCL2 null mice. Brain, Behavior, and Immunity, 2015, 49, 311-321.	3.4	17
134	Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 751-767.	2.3	108
135	AAV2/1 CD74 Gene Transfer Reduces β-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease. Molecular Therapy, 2015, 23, 1712-1721.	6.0	41
136	Influence of age, irradiation and humanization on NSG mouse phenotypes. Biology Open, 2015, 4, 1243-1252.	0.7	27
137	Nano-enabled delivery of diverse payloads across complex biological barriers. Journal of Controlled Release, 2015, 219, 548-559.	8.1	70
138	Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2Rγ c null Mouse Brain Atlas. Journal of NeuroImmune Pharmacology, 2015, 11, 133-141.	3.6	3
139	Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice. Molecular Neurobiology, 2015, 53, 3286-3297.	3.0	19
140	Macrophages Offer A Paradigm Switch for CNS Delivery of Therapeutic Proteins. Nanomedicine, 2014, 9, 1403-1422.	2.5	85
141	Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. Molecular Neurodegeneration, 2014, 9, .	9.9	61
142	Neuromagnetic Evidence of Abnormal Movement-Related Beta Desynchronization in Parkinson's Disease. Cerebral Cortex, 2014, 24, 2669-2678.	1.9	160
143	Small Magnetite Antiretroviral Therapeutic Nanoparticle Probes for MRI of Drug Biodistribution. Nanomedicine, 2014, 9, 1341-1352.	2.5	14
144	Pharmacokinetics, Biodistribution, and Toxicity of Folic Acid-Coated Antiretroviral Nanoformulations. Antimicrobial Agents and Chemotherapy, 2014, 58, 7510-7519.	2.4	22

#	Article	IF	Citations
145	Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Translational Neurodegeneration, 2014, 3, .	8.1	79
146	Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders. Current Opinion in HIV and AIDS, 2014, 9, 585-590.	1.8	18
147	Hypersynchrony despite pathologically reduced beta oscillations in patients with Parkinson's disease: a pharmaco-magnetoencephalography study. Journal of Neurophysiology, 2014, 112, 1739-1747.	1.4	96
148	Bench-To-Bedside Translation of Magnetic Nanoparticles. Nanomedicine, 2014, 9, 501-516.	2.5	64
149	Brain Region Mapping Using Global Metabolomics. Chemistry and Biology, 2014, 21, 1575-1584.	4.7	75
150	Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes. FASEB Journal, 2014, 28, 5071-5082.	2.3	42
151	Endosomal Trafficking of Nanoformulated Antiretroviral Therapy Facilitates Drug Particle Carriage and HIV Clearance. Journal of Virology, 2014, 88, 9504-9513.	2.4	51
152	Formulation Design Facilitates Magnetic Nanoparticle Delivery to Diseased Cells and Tissues. Nanomedicine, 2014, 9, 469-485.	2.5	54
153	An interactive cluster heat map to visualize and explore multidimensional metabolomic data. Metabolomics, 2014, 11, 1029-1034.	1.9	58
154	Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. Journal of NeuroVirology, 2013, 19, 254-260.	1.1	14
155	Improved Visualization of Neuronal Injury Following Glial Activation by Manganese Enhanced MRI. Journal of NeuroImmune Pharmacology, 2013, 8, 1027-1036.	3.6	15
156	Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection. Journal of NeuroImmune Pharmacology, 2013, 8, 1224-1238.	3.6	33
157	Enhancement of NMDA Receptor-Mediated Excitatory Postsynaptic Currents by gp120-Treated Macrophages: Implications for HIV-1-Associated Neuropathology. Journal of NeuroImmune Pharmacology, 2013, 8, 921-933.	3.6	13
158	GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. Journal of Neuroimmunology, 2013, 265, 1-10.	1.7	116
159	Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 1263-1273.	2.3	87
160	Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2013, 57, 3110-3120.	2.4	74
161	CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1060-1068.	2.4	86
162	Functional Proteome of Macrophage Carried Nanoformulated Antiretroviral Therapy Demonstrates Enhanced Particle Carrying Capacity. Journal of Proteome Research, 2013, 12, 2282-2294.	2.2	20

#	Article	IF	Citations
163	Long-Acting Parenteral Nanoformulated Antiretroviral Therapy: Interest and Attitudes of HIV-Infected Patients. Nanomedicine, 2013, 8, 1807-1813.	2.5	100
164	Specific Transfection of Inflamed Brain by Macrophages: A New Therapeutic Strategy for Neurodegenerative Diseases. PLoS ONE, 2013, 8, e61852.	1.5	137
165	Inflammation and Adaptive Immunity in Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009381-a009381.	2.9	246
166	Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. Aids, 2012, 26, 2135-2144.	1.5	126
167	Rodent models for HIV-associated neurocognitive disorders. Trends in Neurosciences, 2012, 35, 197-208.	6.8	76
168	A model of nitric oxide induced α-synuclein misfolding in Parkinson's disease. Neuroscience Letters, 2012, 523, 167-173.	1.3	40
169	Rapid and reliable quantitation of amino acids and myo-inositol in mouse brain by high performance liquid chromatography and tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 893-894, 15-20.	1.7	32
170	Changes in the plasma proteome follows chronic opiate administration in simian immunodeficiency virus infected rhesus macaques. Drug and Alcohol Dependence, 2012, 120, 105-112.	0.8	11
171	Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson's Disease. PLoS ONE, 2012, 7, e38113.	1.5	128
172	CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson's Disease. Journal of NeuroImmune Pharmacology, 2012, 7, 927-938.	3.6	327
173	Plasma Proteomic Profiling in HIV-1 Infected Methamphetamine Abusers. PLoS ONE, 2012, 7, e31031.	1.5	22
174	Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1–Infected Human Peripheral Blood Lymphocyte–Reconstituted Mice. Journal of Infectious Diseases, 2012, 206, 1577-1588.	2.2	67
175	Can Humanized Mice Reflect the Complex Pathobiology of HIV-Associated Neurocognitive Disorders?. Journal of NeuroImmune Pharmacology, 2012, 7, 352-362.	3.6	29
176	Macrophage Bridging Conduit Trafficking of HIV-1 Through the Endoplasmic Reticulum and Golgi Network. Journal of Proteome Research, 2011, 10, 3225-3238.	2.2	76
177	Pulsed Stable Isotope Labeling of Amino Acids in Cell Culture Uncovers the Dynamic Interactions between HIV-1 and the Monocyte-Derived Macrophage. Journal of Proteome Research, 2011, 10, 2852-2862.	2.2	20
178	Neuroprotective activities of regulatory T cells. Trends in Molecular Medicine, 2011, 17, 687-688.	6.4	50
179	BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Neuroscience, 2011, 180, 293-304.	1.8	10
180	Fusobacterium necrophorum causing infective endocarditis and liver and splenic abscesses. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2011, 53, 169-172.	0.5	20

#	Article	IF	Citations
181	Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson?s Disease. Journal of Nanomedicine & Nanotechnology, 2011, 01, .	1.3	65
182	Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. Journal of Controlled Release, 2011, 150, 204-211.	8.1	108
183	Brain ingress of regulatory T cells in a murine model of HIV-1 encephalitis. Journal of Neuroimmunology, 2011, 230, 33-41.	1.7	28
184	Proteomic biosignatures for monocyte–macrophage differentiation. Cellular Immunology, 2011, 271, 239-255.	1.5	20
185	Human Immunodeficiency Virus type 1 Endocytic Trafficking Through Macrophage Bridging Conduits Facilitates Spread of Infection. Journal of NeuroImmune Pharmacology, 2011, 6, 658-675.	3.6	82
186	UPLC–MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2332-2338.	1.7	34
187	Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice. Journal of Neuroscience, 2011, 31, 3148-3157.	2.3	117
188	Cell-Mediated Transfer of Catalase Nanoparticles From Macrophages to Brain Endothelial, Glial and Neuronal Cells. Nanomedicine, 2011, 6, 1215-1230.	2.5	72
189	Macrophage Endocytic Trafficking of Antiretroviral Nanoparticles. Nanomedicine, 2011, 6, 975-994.	2.5	64
190	Pathways towards an effective immunotherapy for Parkinson's disease. Expert Review of Neurotherapeutics, 2011, 11, 1703-1715.	2.3	30
191	Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. Nanotoxicology, 2011, 5, 592-605.	2.2	26
192	Murine Motor and Behavior Functional Evaluations for Acute 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Intoxication. Journal of NeuroImmune Pharmacology, 2011, 7, 279-288.	3.6	46
193	Methamphetamine-Associated Psychosis. Journal of NeuroImmune Pharmacology, 2011, 7, 113-139.	3.6	226
194	Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs. Journal of Visualized Experiments, 2010, , .	0.2	17
195	Molecular mechanisms involving sigma receptor–mediated induction of MCP-1: implication for increased monocyte transmigration. Blood, 2010, 115, 4951-4962.	3.6	119
196	Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring. Journal of Visualized Experiments, 2010, , .	0.2	4
197	Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics. Journal of NeuroImmune Pharmacology, 2010, 5, 592-601.	3.6	100
198	Immunoregulation of a CB2 Receptor Agonist in a Murine Model of NeuroAIDS. Journal of NeuroImmune Pharmacology, 2010, 5, 456-468.	3.6	50

#	Article	IF	Citations
199	Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. Journal of Controlled Release, 2010, 143, 290-301.	8.1	150
200	HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiology of Disease, 2010, 37, 542-548.	3.5	86
201	Rebuilding Synaptic Architecture in HIV-1 Associated Neurocognitive Disease: A Therapeutic Strategy Based on Modulation of Mixed Lineage Kinase. Neurotherapeutics, 2010, 7, 392-398.	3.9	12
202	Proteomic analyses of monocytes obtained from Hispanic women with HIV-associated dementia show depressed antioxidants. Proteomics - Clinical Applications, 2010, 4, 706-714.	1.5	24
203	Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. Journal of Neurochemistry, 2010, 114, 1261-1276.	2.7	37
204	Plasma Proteomic Analysis of Simian Immunodeficiency Virus Infection of Rhesus Macaques. Journal of Proteome Research, 2010, 9, 4721-4731.	2.2	21
205	CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB Journal, 2010, 24, 3093-3102.	2.3	210
206	Functional Proteomic Analysis for Regulatory T Cell Surveillance of the HIV-1-Infected Macrophage. Journal of Proteome Research, 2010, 9, 6759-6773.	2.2	29
207	Macrophage Delivery of Therapeutic Nanozymes in A Murine Model of Parkinson'S Disease. Nanomedicine, 2010, 5, 379-396.	2.5	178
208	Links between Progressive HIV-1 Infection of Humanized Mice and Viral Neuropathogenesis. American Journal of Pathology, 2010, 177, 2938-2949.	2.8	106
209	Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring. Journal of Visualized Experiments, 2010, , .	0.2	0
210	Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs. Journal of Visualized Experiments, 2010, , .	0.2	0
211	CCL2 Accelerates Microglia-Mediated Aβ Oligomer Formation and Progression of Neurocognitive Dysfunction. PLoS ONE, 2009, 4, e6197.	1.5	111
212	Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS. Journal of Immunology, 2009, 183, 661-669.	0.8	227
213	Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease. Antioxidants and Redox Signaling, 2009, 11, 2151-2166.	4.1	127
214	AAV1/2-mediated CNS Gene Delivery of Dominant-negative CCL2 Mutant Suppresses Gliosis, β-amyloidosis, and Learning Impairment of APP/PS1 Mice. Molecular Therapy, 2009, 17, 803-809.	6.0	69
215	Simvastatin Inhibits the Activation of p21rasand Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease. Journal of Neuroscience, 2009, 29, 13543-13556.	2.3	175
216	NanoART synthesis, characterization, uptake, release and toxicology for human monocyte–macrophage drug delivery. Nanomedicine, 2009, 4, 903-917.	2.5	122

#	Article	IF	Citations
217	CD 4+ T cells in the pathobiology of neurodegenerative disorders. Journal of Neuroimmunology, 2009, 211, 3-15.	1.7	49
218	Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. Journal of Neuroimmunology, 2009, 213, 47-59.	1.7	24
219	HIV-1 transforms the monocyte plasma membrane proteome. Cellular Immunology, 2009, 258, 44-58.	1.5	26
220	4-Aminopyridine Improves Spatial Memory in a Murine Model of HIV-1 Encephalitis. Journal of NeuroImmune Pharmacology, 2009, 4, 317-327.	3.6	24
221	Lithium therapy for human immunodeficiency virus type 1–associated neurocognitive impairment. Journal of NeuroVirology, 2009, 15, 176-186.	1.1	98
222	A Coat of Many Colors: Neuroimmune Crosstalk in Human Immunodeficiency Virus Infection. Neuron, 2009, 64, 133-145.	8.2	114
223	NanoART, NeuroAIDS and CNS Drug Delivery. Nanomedicine, 2009, 4, 557-574.	2.5	121
224	Neurodegenerative Disorders and Nanoformulated Drug Development. Nanomedicine, 2009, 4, 541-555.	2.5	65
225	Proteomic Studies of Nitrated Alpha-Synuclein Microglia Regulation by CD4+CD25+ T Cells. Journal of Proteome Research, 2009, 8, 3497-3511.	2.2	79
226	Facilitated Monocyte-Macrophage Uptake and Tissue Distribution of Superparmagnetic Iron-Oxide Nanoparticles. PLoS ONE, 2009, 4, e4343.	1.5	118
227	Nitrated Alpha-Synuclein and Microglial Neuroregulatory Activities. Journal of NeuroImmune Pharmacology, 2008, 3, 59-74.	3.6	120
228	Disseminating Research Discovery Through an Interactive Video: a Paradigm Shift for Journal Publication. Journal of NeuroImmune Pharmacology, 2008, 3, 57-57.	3.6	0
229	HIV-1-Infected Astrocytes and the Microglial Proteome. Journal of NeuroImmune Pharmacology, 2008, 3, 173-186.	3.6	48
230	Modulation of innate immunity by copolymer-1 leads to neuroprotection in murine HIV-1 encephalitis. Glia, 2008, 56, 223-232.	3.6	20
231	Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. Journal of Neurochemistry, 2008, 104, 1504-1525.	2.7	210
232	Ingress of blood-borne macrophages across the blood-brain barrier in murine HIV-1 encephalitis. Journal of Neuroimmunology, 2008, 200, 41-52.	1.7	17
233	Erratum to "CSF proteomic fingerprints for HIV-associated cognitive impairment". Journal of Neuroimmunology, 2008, 205, 161.	1.7	0
234	Proteomic Analyses Associate Cystatin B with Restricted HIV-1 Replication in Placental Macrophages. Placenta, 2008, 29, 1016-1023.	0.7	43

#	Article	IF	Citations
235	Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons. PLoS ONE, 2008, 3, e1376.	1.5	357
236	Multidimensional protein fractionation using ProteomeLab PF 2D™ for profiling amyotrophic lateral sclerosis immunity: A preliminary report. Proteome Science, 2008, 6, .	1.1	20
237	STAT1 signaling modulates HIV-1–induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood, 2008, 111, 2062-2072.	3.6	146
238	Monocyte Chemotactic Protein-1 Regulates Voltage-Gated K+ Channels and Macrophage Transmigration. Journal of NeuroImmune Pharmacology, 2008, 4, 47-59.	3.6	50
239	Proteomic Modeling for HIV-1 Infected Microglia-Astrocyte Crosstalk. PLoS ONE, 2008, 3, e2507.	1.5	48
240	Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice. PLoS ONE, 2008, 3, e2740.	1.5	189
241	The neuropathogenesis of HIV-1 infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, , 45-67.	0.4	11
242	Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 235-242.	2.1	19
243	Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18754-18759.	5.2	434
244	Interferon-γ and Tumor Necrosis Factor-α Regulate Amyloid-β Plaque Deposition and β-Secretase Expression in Swedish Mutant APP Transgenic Mice. American Journal of Pathology, 2007, 170, 680-692.	2.8	379
245	Oxidative Stress and the Pathogenesis of Neurodegenerative Disorders. International Review of Neurobiology, 2007, , 297-325.	0.0	393
246	Cerebrospinal Fluid Proteomic Profiling of HIV-1-Infected Patients with Cognitive Impairment. Journal of Proteome Research, 2007, 6, 4189-4199.	2.2	103
247	A Macrophage–Nanozyme Delivery System for Parkinson's Disease. Bioconjugate Chemistry, 2007, 18, 1498-1506.	2.9	201
248	Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. Journal of Leukocyte Biology, 2007, 82, 1083-1094.	1.7	399
249	T cell independent mechanism for copolymer-1-induced neuroprotection. European Journal of Immunology, 2007, 37, 3143-3154.	2.2	64
250	Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Progress in Polymer Science, 2007, 32, 1054-1082.	20.3	261
251	HIV-1 gp120 Compromises Blood–Brain Barrier Integrity and Enhance Monocyte Migration across Blood–Brain Barrier: Implication for Viral Neuropathogenesis. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 123-134.	3.1	226
252	Novel Delivery System Enhances Efficacy of Antiretroviral Therapy in Animal Model for HIV-1 Encephalitis. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1033-1042.	3.1	68

#	Article	IF	Citations
253	Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. Journal of Neurochemistry, 2007, 100, 503-519.	2.7	125
254	Genomic and proteomic microglial profiling: pathways for neuroprotective inflammatory responses following nerve fragment clearance and activation. Journal of Neurochemistry, 2007, 102, 627-645.	2.7	66
255	Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology, 2007, 358, 148-158.	1.6	92
256	Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology, 2007, 363, 198-209.	1.6	76
257	Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Neurobiology of Disease, 2007, 26, 146-152.	3.5	44
258	Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiology of Disease, 2007, 26, 590-596.	3.5	121
259	CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Journal of Neuroimmunology, 2007, 183, 60-68.	1.7	93
260	HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: New insights into blood–brain barrier dysfunction for HIV-1-associated dementia. Journal of Neuroimmunology, 2007, 185, 37-46.	1.7	69
261	CSF proteomic fingerprints for HIV-associated cognitive impairment. Journal of Neuroimmunology, 2007, 192, 157-170.	1.7	60
262	Biomarkers, Laboratory, and Animal Models for the Design and Development of Adjunctive Therapies for HIV-1 Dementia and other Neuroinflammatory Disorders. Journal of NeuroImmune Pharmacology, 2007, 2, 8-13.	3.6	13
263	The Journal of Neuroimmune Pharmacology Reaches Its Stride. Journal of NeuroImmune Pharmacology, 2007, 2, 129-130.	3.6	0
264	A Functional Transsulfuration Pathway in the Brain Links to Glutathione Homeostasis. Journal of Biological Chemistry, 2006, 281, 35785-35793.	1.3	227
265	Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood, 2006, 108, 2827-2835.	3.6	257
266	Debate: "Is Increasing Neuroinflammation Beneficial for Neural Repair?". Journal of NeuroImmune Pharmacology, 2006, 1, 195-211.	3.6	64
267	Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System. Journal of NeuroImmune Pharmacology, 2006, 1, 340-350.	3.6	254
268	Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson's disease. Clinical Neuroscience Research, 2006, 6, 261-281.	1.0	349
269	Neuropathologic and neuroinflammatory activities of HIV-1-infected human astrocytes in murine brain. Glia, 2006, 54, 81-93.	3.6	34
270	HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1β. Glia, 2006, 54, 619-629.	3.6	97

#	Article	IF	Citations
271	Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report. Neurology, 2006, 66, 919-921.	0.7	114
272	Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. Journal of Leukocyte Biology, 2006, 80, 1165-1174.	1.7	66
273	Monocyte Differentiation, Activation, and Mycobacterial Killing Are Linked to Transsulfuration-dependent Redox Metabolism. Journal of Biological Chemistry, 2006, 281, 38712-38720.	1.3	34
274	Glycogen Synthase Kinase 3 Beta (GSK-3β) as a Therapeutic Target in NeuroAIDS. Journal of NeuroImmune Pharmacology, 2006, 2, 93-96.	3.6	42
275	Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood, 2005, 106, 2382-2390.	3.6	149
276	HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death and Differentiation, 2005, 12, 878-892.	7.4	348
277	Development of a rapid autopsy program for studies of brain immunity. Journal of Neuroimmunology, 2005, 163, 135-144.	1.7	20
278	Neuroinflammatory responses from microglia recovered from HIV-1-infected and seronegative subjects. Journal of Neuroimmunology, 2005, 163, 145-156.	1.7	29
279	Proteomic fingerprints distinguish microglia, bone marrow, and spleen macrophage populations. Glia, 2005, 51, 161-172.	3.6	30
280	Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis. Glia, 2005, 52, 344-353.	3.6	55
281	Coregistration of quantitative proton magnetic resonance spectroscopic imaging with neuropathological and neurophysiological analyses defines the extent of neuronal impairments in murine human immunodeficiency virus type-1 encephalitis. Journal of Neuroscience Research, 2005, 80, 562-575.	2.0	15
282	Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. Neurotoxicity Research, 2005, 8, 25-50.	2.4	66
283	Human Dendritic Cells Transduced with Herpes Simplex Virus Amplicons Encoding Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Elicit Adaptive Immune Responses from Human Cells Engrafted into NOD/SCID Mice and Confer Partial Protection against HIV-1 Challenge. Journal of Virology, 2005, 79, 2124-2132.	2.4	46
284	Neuroprotective Mechanisms of Lithium in Murine Human Immunodeficiency Virus-1 Encephalitis. Journal of Neuroscience, 2005, 25, 8375-8385.	2.3	78
285	Quantitative 1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease. Journal of Neuroscience, 2005, 25, 1691-1700.	2.3	76
286	Overexpression of Monocyte Chemotactic Protein-1/CCL2 in β-Amyloid Precursor Protein Transgenic Mice Show Accelerated Diffuse β-Amyloid Deposition. American Journal of Pathology, 2005, 166, 1475-1485.	2.8	144
287	Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9435-9440.	5.2	316
288	Proteomic fingerprinting of human immunodeficiency virus type 1–associated dementia from patient monocyte-derived macrophages: A case study. Journal of NeuroVirology, 2004, 10, 74-81.	1.1	21

#	Article	IF	Citations
289	Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. Journal of NeuroVirology, 2004, 10, 82-90.	1.1	20
290	Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. Journal of NeuroVirology, 2004, 10, 82-90.	1.1	3
291	Proteomic fingerprinting of human immunodeficiency virus type 1?associated dementia from patient monocyte-derived macrophages: A case study. Journal of NeuroVirology, 2004, 10, 74-81.	1.1	20
292	Proteomic fingerprinting of HIV-1-infected human monocyte-derived macrophages: a preliminary report. Journal of Neuroimmunology, 2004, 147, 35-42.	1.7	21
293	TNF-related apoptosis-inducing ligand mediates human neuronal apoptosis: links to HIV-1-associated dementia. Journal of Neuroimmunology, 2004, 148, 127-139.	1.7	57
294	OTK18 expression in brain mononuclear phagocytes parallels the severity of HIV-1 encephalitis. Journal of Neuroimmunology, 2004, 150, 186-198.	1.7	22
295	Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease. Journal of Neuroimmunology, 2004, 157, 11-16.	1.7	36
296	Proteomic fingerprinting of human immunodeficiency virus type 1-associated dementia from patient monocyte-derived macrophages: A case study. Journal of NeuroVirology, 2004, 10, 74-81.	1.1	18
297	Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. Journal of NeuroVirology, 2004, 10, 82-90.	1.1	23
298	Neuroprotective strategies for HIV-1 associated dementia. Neurotoxicity Research, 2004, 6, 503-521.	2.4	29
299	C1q–calreticulin induced oxidative neurotoxicity: relevance for the neuropathogenesis of Alzheimer's disease. Journal of Neuroimmunology, 2003, 135, 62-71.	1.7	51
300	Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. Journal of Neuroimmunology, 2003, 138, 144-155.	1.7	84
301	Peripheral nerve induces macrophage neurotrophic activities: regulation of neuronal process outgrowth, intracellular signaling and synaptic function. Journal of Neuroimmunology, 2003, 142, 112-129.	1.7	35
302	Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: Links to HIV-1 dementia. Glia, 2003, 44, 47-56.	3.6	97
303	Inhibition of long-term potentiation by interleukin-8: Implications for human immunodeficiency virus-1-associated dementia. Journal of Neuroscience Research, 2003, 71, 600-607.	2.0	60
304	Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance imaging. Journal of Neuroscience Research, 2003, 73, 284-295.	2.0	87
305	Activation of NR1a/NR2B receptors by monocyte-derived macrophage secretory products: implications for human immunodeficiency virus type one-associated dementia. Neuroscience Letters, 2003, 341, 246-250.	1.3	15
306	Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis. Neuroscience, 2003, 118, 359-369.	1.8	46

#	Article	IF	Citations
307	Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. Journal of Leukocyte Biology, 2003, 74, 691-701.	1.7	156
308	Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment. Neurology, 2003, 60, 1931-1937.	0.7	76
309	Non-neuronal interactions in HIV-1-associated dementia. Advances in Molecular and Cell Biology, 2003, , 901-920.	0.4	1
310	Neuroprotective Activities of Sodium Valproate in a Murine Model of Human Immunodeficiency Virus-1 Encephalitis. Journal of Neuroscience, 2003, 23, 9162-9170.	2.3	117
311	Neuroimaging and Proteomic Tracking of Neurodegeneration in MPTP-Treated Mice. Annals of the New York Academy of Sciences, 2003, 991, 319-321.	2.6	2
312	HIV-1–Associated Dementia: A Metabolic Encephalopathy Perpetrated by Virus-Infected and Immune-Competent Mononuclear Phagocytes. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S43-S54.	1.2	136
313	Impaired Spatial Cognition and Synaptic Potentiation in a Murine Model of Human Immunodeficiency Virus Type 1 Encephalitis. Journal of Neuroscience, 2002, 22, 2096-2105.	2.3	73
314	Mononuclear phagocyte biophysiology influences brain transendothelial and tissue migration: implication for HIV-1-associated dementia. Journal of Neuroimmunology, 2002, 122, 40-54.	1.7	29
315	HIV-1 infected and immune competent mononuclear phagocytes induce quantitative alterations in neuronal dendritic arbor: Relevance for HIV-1-associated dementia. Neurotoxicity Research, 2001, 3, 443-459.	2.4	36
316	HIV-1 infected immune competent mononuclear phagocytes influence the pathways to neuronal demise. Neurotoxicity Research, 2001, 3, 461-484.	2.4	35
317	The Efficacy of Potent Anti-retroviral Drug Combinations Tested in a Murine Model of HIV-1 Encephalitis. Virology, 2001, 281, 21-34.	1.6	17
318	Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFα inhibitor in SCID mice with HIV-1 encephalitis. Journal of Neuroimmunology, 2001, 114, 57-68.	1.7	66
319	Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages. Journal of Neuroimmunology, 2001, 117, 97-107.	1.7	137
320	The regulation of alpha chemokines during HIV-1 infection and leukocyte activation: relevance for HIV-1-associated dementia. Journal of Neuroimmunology, 2001, 120, 112-128.	1.7	43
321	Plasma Levels of Soluble CD14 and Tumor Necrosis Factor–α Type II Receptor Correlate with Cognitive Dysfunction during Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 2001, 184, 699-706.	2.2	92
322	Regulation of Human Immunodeficiency Virus Type 1 Infection, β-Chemokine Production, and CCR5 Expression in CD40L-Stimulated Macrophages: Immune Control of Viral Entry. Journal of Virology, 2001, 75, 4308-4320.	2.4	46
323	Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice. Neurology, 2000, 54, 379-379.	0.7	43
324	Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity. Journal of Leukocyte Biology, 1999, 65, 416-427.	1.7	80

#	Article	IF	Citations
325	Unraveling the Mechanisms of Neurotoxicity in HIV Type 1-Associated Dementia: Inhibition of Neuronal Synaptic Transmission by Macrophage Secretory Products. AIDS Research and Human Retroviruses, 1999, 15, 57-63.	0.9	23
326	HIV-Associated Dementia: New Insights into Disease Pathogenesis and Therapeutic Interventions. AIDS Patient Care and STDs, 1999, 13, 153-163.	2.1	42
327	The neuropathogenesis of HIV-1 infection. FEMS Immunology and Medical Microbiology, 1999, 26, 233-241.	3.0	65
328	Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. Journal of Neuroimmunology, 1999, 98, 185-200.	1.7	308
329	Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice. Vaccine, 1999, 17, 64-71.	2.0	12
330	Microglial and Astrocyte Chemokines Regulate Monocyte Migration through the Blood-Brain Barrier in Human Immunodeficiency Virus-1 Encephalitis. American Journal of Pathology, 1999, 155, 1599-1611.	2.8	280
331	The cellular immunology of multiple sclerosis. Journal of Leukocyte Biology, 1999, 65, 444-452.	1.7	52
332	Innate and acquired immunity in neurodegenerative disorders. Journal of Leukocyte Biology, 1999, 65, 407-408.	1.7	18
333	Review: Neuronal injury in HIV infection. Journal of NeuroVirology, 1999, 5, 327-341.	1.1	42
334	Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: a mechanism for cognitive dysfunction in HIV-1-associated dementia. Journal of NeuroVirology, 1999, 5, 519-528.	1.1	41
335	The neuropathogenesis of HIV-1 infection. FEMS Immunology and Medical Microbiology, 1999, 26, 233-241.	3.0	3
336	Suppression of Inflammatory Neurotoxins by Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Associated Dementia. Journal of Infectious Diseases, 1998, 178, 1000-1007.	2.2	170
337	SCID Mice With HIV Encephalitis Develop Behavioral Abnormalities. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 13-20.	0.3	51
338	Human Immunodeficiency Virus Neurotropism: an Analysis of Viral Replication and Cytopathicity for Divergent Strains in Monocytes and Microglia. Journal of Virology, 1998, 72, 3340-3350.	2.4	102
339	Role of the β-Chemokine Receptors CCR3 and CCR5 in Human Immunodeficiency Virus Type 1 Infection of Monocytes and Microglia. Journal of Virology, 1998, 72, 3351-3361.	2.4	148
340	Dexamethasone Therapy Worsens the Neuropathology of Human Immunodeficiency Virus Type 1 Encephaliti in SCID Mice. Journal of Infectious Diseases, 1997, 175, 1368-1381.	2.2	29
341	The HIV-1 associated dementia complex. Current Opinion in Neurology, 1997, 10, 319-326.	2.4	75
342	An analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID mice with HIV-1 encephalitis. Journal of NeuroVirology, 1997, 3, 401-416.	1.1	122

#	Article	IF	Citations
343	Development of laboratory and animal model systems for HIV-1 encephalitis and its associated dementia. Journal of Leukocyte Biology, 1997, 62, 100-106.	1.7	54
344	Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 700-704.	5.2	296
345	The regulation of quinolinic acid in human immunodeficiency virus-infected monocytes. Journal of NeuroVirology, 1996, 2, 111-117.	1.1	39
346	Regulation and Characterization of the Interferon-α Present in Patients with Advanced Human Immunodeficiency Virus Type 1 Disease. Journal of Interferon and Cytokine Research, 1996, 16, 127-137.	1.0	14
347	Efficient synthesis of viral nucleic acids following monocyte infection by HIV-1. Virology, 1995, 206, 731-735.	1.6	42
348	Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Trends in Immunology, 1995, 16, 441-448.	6.9	114
349	The development of animal model systems for HIV-1 encephalitis and its associated dementia. Journal of NeuroVirology, 1995, 1, 229-243.	1.1	39
350	Utility of cerebral proton magnetic resonance spectroscopy in differential diagnosis of HIV-related dementia. Journal of NeuroVirology, 1995, 1, 268-274.	1.1	12
351	Dementia Associated with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1995, 332, 934-940.	26.4	481
352	The neuroimmune mechanisms for HIV-tπ dementia: The role of mononuclear phagocytes and astrocytes in virus-related brain disease. Journal of Neuroimmunology, 1995, 63, 99.	1.7	0
353	Prospective Utility of Cerebral Proton Magnetic Resonance Spectroscopy in Monitoring HIV Infection and Its Associated Neurological Impairment. AIDS Research and Human Retroviruses, 1994, 10, 977-982.	0.9	67
354	Reply. Annals of Neurology, 1994, 35, 125-126.	4.6	1
355	An experimental model system for HIV-1-induced brain injury. Advances in Neuroimmunology, 1994, 4, 189-193.	1.7	59
356	Regulation of HIV1 replication by interferon alpha: From laboratory bench to bedside. Research in Immunology, 1994, 145, 679-685.	0.8	8
357	Regulation of interferon-α-inducible cellular genes in human immunodeficiency virus-infected monocytes. Journal of Leukocyte Biology, 1994, 55, 299-309.	1.7	58
358	The neuropathogenesis of HIV-1 infection. Journal of Leukocyte Biology, 1994, 56, 389-398.	1.7	254
359	Cellular and viral determinants that regulate HIV-1 infection in macrophages. Journal of Leukocyte Biology, 1994, 56, 278-288.	1.7	45
360	Alpha interferon-induced antiretroviral activities: restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes. Journal of Virology, 1994, 68, 7559-7565.	2.4	92

#	Article	IF	Citations
361	Human immunodeficiency virus type 1 infection of the nervous system: Pathogenetic mechanisms. Annals of Neurology, 1993, 33, 429-436.	4.6	383
362	A model of human immunodeficiency virus encephalitis in scid mice.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 8658-8662.	5.2	127
363	HIV infection of the lung. Role of virus-infected macrophages in the pathophysiology of pulmonary disease. Chest, 1993, 103, 103S-108.	0.8	20
364	No Direct Neuronotoxicity by HIV-1 Virions or Culture Fluids from HIV-1-Infected T Cells or Monocytes. AIDS Research and Human Retroviruses, 1992, 8, 495-503.	0.9	50
365	Interferons in the Persistence, Pathogenesis, and Treatment of HIV Infection. AIDS Research and Human Retroviruses, 1992, 8, 199-207.	0.9	122
366	Human immunodeficiency virus type 1 infection of neural xenografts.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 5162-5166.	5.2	31
367	Interferon alpha (IFN)-Macrophage Interactions in Human Immunodeficiency Virus (HIV) Infection: Role of IFN in the Tempo and Progression of HIV Disease. International Reviews of Immunology, 1992, 8, 43-54.	2.7	15
368	Virus-cell membrane fusion does not predict efficient infection of alveolar macrophages by human immunodeficiency virus type 1 (HIV-1). Virology, 1992, 188, 864-868.	1.6	33
369	Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120. Journal of Virology, 1992, 66, 7543-7548.	2.4	67
370	Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. Journal of Virology, 1992, 66, 3925-3931.	2.4	143
371	Monocytes, Dendritic Cells, and Langerhans Cells in Human Immunodeficiency Virus Infection. Dermatologic Clinics, 1991, 9, 415-428.	1.8	23
372	HIV Replication and Persistence in Human Gastrointestinal Cells Cultured In Vitro. Journal of Leukocyte Biology, 1991, 49, 499-504.	1.7	25
373	Inhibition of human immunodeficiency virus infection in monocytes by monoclonal antibodies against leukocyte adhesion molecules. Immunology Letters, 1991, 30, 219-227.	1.6	42
374	Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 3097-3101.	5.2	351
375	The inability of human immunodeficiency virus to infect chimpanzee monocytes can be overcome by serial viral passage in vivo. Journal of Virology, 1991, 65, 3853-3863.	2.4	43
376	Macrophage-HIV interaction. Aids, 1990, 4, 221-228.	1.5	66
377	Macrophages and the human immunodeficiency virus. Trends in Immunology, 1990, 11, 217-223.	6.9	174
378	Restriction of HIV Replication in Infected T Cells and Monocytes by Interferon-α. AIDS Research and Human Retroviruses, 1990, 6, 1045-1049.	0.9	64

#	Article	IF	Citations
379	Macrophages as Susceptible Targets for HIV Infection, Persistent Viral Reservoirs in Tissue, and Key Immunoregulatory Cells that Control Levels of Virus Replication and Extent of Disease. AIDS Research and Human Retroviruses, 1990, 6, 967-971.	0.9	114
380	Infection of Human Gastrointestinal Cells by HIV-1. AIDS Research and Human Retroviruses, 1990, 6, 1409-1415.	0.9	59
381	Role of Mononuclear Phagocytes in the Pathogenesis of Human Immunodeficiency Virus Infection. Annual Review of Immunology, 1990, 8, 169-194.	22.3	285
382	Development of an in Vitro Human Monocyte-Derived Macrophage-Based System for Drug Screening against HIV-1. Annals of the New York Academy of Sciences, 1990, 616, 597-598.	2.6	0
383	AIDS-associated progressive multifocal leukoencephalopathy (PML). Neurology, 1990, 40, 1073-1073.	0.7	61
384	The Human Immunodeficiency Virus Long Terminal Repeat Is Preferentially Expressed in Langerhans Cells in Transgenic Mice. AIDS Research and Human Retroviruses, 1989, 5, 421-430.	0.9	70
385	Human immunodeficiency virus type 1 in spinal cords of acquired immunodeficiency syndrome patients with myelopathy: expression and replication in macrophages.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 3337-3341.	5.2	134
386	Immunopathogenesis of human immunodeficiency virus infection in the central nervous system. Annals of Neurology, 1988, 23, S78-S81.	4.6	34
387	Effects of colony stimulating factors on the interaction of monocytes and the human immunodeficiency virus. Immunology Letters, 1988, 19, 193-198.	1.6	25
388	Molecular pathogenesis of human immunodeficiency virus infection. Gene Analysis Techniques, 1988, 5, 41-53.	1.3	4
389	Activation of the human immunodeficiency virus long terminal repeat by herpes simplex virus type 1 is associated with induction of a nuclear factor that binds to the NF-kappa B/core enhancer sequence. Journal of Virology, 1988, 62, 4104-4112.	2.4	125
390	Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. Journal of Virology, 1988, 62, 2578-2586.	2.4	287
391	Molecular characterization of a polymerase mutant human immunodeficiency virus. Virology, 1987, 160, 323-329.	1.6	48
392	Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. Journal of Virology, 1987, 61, 209-213.	2.4	244
393	Activation of the human immunodeficiency virus by herpes simplex virus type 1. Journal of Virology, 1987, 61, 3726-3732.	2.4	171
394	Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 9759-9763.	5.2	424
395	Tropism of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages. Journal of Virology, 1986, 58, 67-74.	2.4	352
396	Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. Journal of Virology, 1986, 59, 284-291.	2.4	3,143

#	Article	IF	Citations
397	Slow, persistent replication of lentiviruses: role of tissue macrophages and macrophage precursors in bone marrow.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 7086-7090.	5.2	330
398	A quantitation of myelin-associated glycoprotein and myelin basic protein loss in different demyelinating disease. Annals of Neurology, 1985, 18, 324-328.	4.6	57
399	Postinfectious Encephalomyelitis. Seminars in Neurology, 1985, 5, 180-190.	1.2	83
400	A double labeling technique for performing immunocytochemistry and in situ hybridization in virus infected cell cultures and tissues. Journal of Virological Methods, 1985, 11, 93-103.	1.0	77
401	Efficiency of in situ hybridization as a function of probe size and fixation technique. Journal of Virological Methods, 1985, 11, 119-130.	1.0	110
402	Measles encephalomyelitis: Lack of evidence of viral invasion of the central nervous system and quantitative study of the nature of demyelination. Annals of Neurology, 1984, 15, 353-360.	4.6	110
403	Selection of a fixative for identifying T cell subsets, B cells, and macrophages in paraffin-embedded mouse spleen. Journal of Immunological Methods, 1983, 65, 137-145.	1.0	90
404	Title is missing!. , 0, .		1
405	Innate Immunity and Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 0, 16, a041640.	2.9	3
406	Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV-1 Proviral DNA Excision. Advanced Healthcare Materials, 0, 14, .	6.6	4
407	The promise and perils of humanized mice: workshop report from the 29th scientific conference of the society on NeuroImmune pharmacology (SNIP). NeuroImmune Pharmacology and Therapeutics, 0, 4, 315-324.	0.7	0
408	Regulatory T cell α(1,3)-exofucosylation for treatment of neurodegenerative diseases. Journal of Leukocyte Biology, 0, 117, .	1.7	2
409	Searching for a HIV-1 Cure. Theranostics, 0, 16, 2170-2191.	8.1	5
410	Extracellular vesicle-based therapies for neurodegenerative diseases. NeuroImmune Pharmacology and Therapeutics, 0, 4, 377-390.	0.7	5
411	CAR Treg therapies for neurodegenerative diseases. IScience, 0, 29, 114988.	2.4	7
412	Colostrum Extracellular Vesicle Isolation, Characterization, and Function. Biomedicines, 0, 14, 1549.	2.5	0
413	Combinatorial Therapy with Long-Acting Tenofovir and Tizoxanide Controls Viral Replication and Liver Inflammation in a Murine AAV-HBV Model of Chronic Hepatitis B. Biology, 0, 15, 1391.	2.2	0